Thejna John is a happy woman. Last year, the relapse of an acute form of blood cancer despite a bone marrow transplant, had made her doctors give up all hope.

In October, came a breakthrough. India approved the CAR T-Cell therapy, a revolutionary treatment for some forms of cancer. Thejna was one of the first cancer patients to undergo treatment in India. She is now cancer-free.

The potential of CAR T-cell therapy is significant. And Pharma majors from Dr Reddy’s to Biocon are pouring in money into their own CAR T-Cell projects. But it’s early days. And questions remain: on efficacy, relapse, neurotoxicity and high costs.

Join the conversation with host Anirban Chowdhury, Vikas Dandekar, ET's pharma expert, along with CAR T-Cell pioneer Dr. Hasmukh Jain, Associate Professor - Tata Memorial Centre, and Shirish Arya, Chief Business Officer - ImmunoACT as they discuss the future of this life-saving treatment on The Morning Brief podcast!

Credits: TED

If you like this episode from Anirban Chowdhury, check out his other interesting episodes on Fatigued & Flying: Why tired pilots are a wake-up call, Vizhinjam Port: Can Adani make India a global shipping hub?, Bhilai to Burj: The Rs. 5,000 Cr Bollywood Studded Mahadev Book Scam and more!

You can follow Anirban Chowdhury on his social media: Twitter and Linkedin

Catch the latest episode of ‘The Morning Brief’ on ET Play, The Economic Times Online, Spotify, Apple Podcasts, Amazon Music and Google Podcasts.

See omnystudio.com/listener for privacy information.

The Unlikely Pioneer Behind mRNA Vaccine...